Blog Unraveling the Power of Germline Clinico-Genomic Data: A Game Changer in Pharma's Drug Development Lifecycle
Press ReleasesHelix Launches World's Largest Clinico-Genomic Cohort of GLP-1 Agonist Treated PatientsFebruary 3, 2025
Press ReleasesThe Helix Research Network Adds Three New Health System Members, Transforming Clinical Genomics for Community BenefitJanuary 15, 2025
Press ReleasesHelix Debuts Novel Precision Effectiveness Model That Predicts 12-Month Weight Loss Response of Semaglutide in Diverse PopulationsNovember 13, 2024
VideosPartner Perspectives with Nebraska MedicineGenetic Insights Project helps Nebraskans take charge of their health
1Published ResearchUnderestimated risk of secondary complications in pathogenic and glucose-elevating GCK variant carriers with type 2 diabetesNovember 21, 2024
2Published ResearchHelix Debuts Novel Precision Effectiveness Model That Predicts 12-Month Weight Loss Response of Semaglutide in Diverse PopulationsNovember 13, 2024
3Published ResearchA novel method for predicting Lp(a) levels from routine outpatient genomic testing identifies those at risk of cardiovascular disease across a diverse cohortNovember 4, 2024
4Published ResearchInfluence of BMI-associated genetic variants and metabolic risk factors on weight loss with semaglutide: a longitudinal clinico-genomic cohort studyNovember 3, 2024
5Published ResearchHelix to Showcase the Impact of Clinico-Genomic Research on Clinical Care and Drug Discovery at ASHG Annual MeetingOctober 30, 2024